GET THE APP

Magnetic nanoparticle/ magnetic fluid approach to contr

Journal of Nanomaterials & Molecular Nanotechnology.ISSN: 2324-8777

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Magnetic nanoparticle/ magnetic fluid approach to control neuromuscular degeneration in Friedreich’s ataxia


Swasti Wagh and D K Wagh

Seek a Miracle Ataxia Group, India
Govindram Seksaria Inst. of Tech. & Sc., Indore, India
: J Nanomater Mol Nanotechnol

Abstract


In last two decades nanotechnology has brought a revolution in the advancement of material science, biology, biotechnology, genetics, medicine and many other areas of science and engineering. The ability of nanotechnologist to prepare material particles of nano size, coating them with a suitable surfactant and magnetizing these particles has made possible to study micro level biological entities such as cells, genes and proteins. In recent years magnetic nanoparticles have been used in cancer treatment, drug delivery and in many other medical fields. This leads us to think why this technology should not be introduced in F.A. research for which no treatment is available and patients suffer with lethal neuro- degenerarative condition of F.A. making them totally dependent on others for even the simple day to day activities. The disease is genetic and unknowingly passes on in off-springs through the carrier parents. It is therefore necessary to control degeneration in F.A. patients and make their life comfortable. Friedreich’s ataxia (FRDA) is an autosomal recessive inherited disease caused by (GAA) expansion of the FXN (frataxin) gene. FRDA is predominantly a neurodegenerative disease. It manifests in initial symptoms of poor coordination such as gait disturbance; it can also lead to scoliosis, heart disease (cardiomyopathy) and diabetes. FXN gene produces frataxin protein which is localized to the mitochondria. The function of FXN is not entirely clear, however, the primary role of FXN protein is the activation of iron-sulfur (Fe-S) cluster biogenesis in the mitochondria. In F.R.D.A. production of FXN protein is reduced. In affected individuals level of FXN drops approximately 5 to 30% than healthy individuals. The role of FXN protein is that of an iron chaperone, a companion of iron particle. Low FXN levels lead to insufficient biosynthesis of iron-sulfur clusters that are required for mitochondrial electron transport chain to ultimately generate adenosine triphosphate (ATP), the energy packet necessary to carry out metabolic functions in cells. FXN also regulates iron transfer in the mitochondria in order to provide a proper amount of reactive oxygen species (ROS) to maintain normal processes without FXN, the energy in the mitochondria falls, and excess iron causes extra ROS to be created, leading to further cell damage. Nanotechnology can be useful to solve this problem. We can introduce body compatible magnetic nanoparticles to pickup iron particles and direct them to sulpher to form iron-sulpher clusters. Thus iron-sulpher clusters can be formed even in the absence of FXN protein in F.A. patients. And thus the process of respiration in mitochondria will continue to produce energy in the form of ATP. As iron particles are utilized in formation of iron-sulpher clusters no free iron is left to get deposited on cells and cause cell death in FRDA patents.

Biography


Swasti Wagh has completed her MSc in Applied Mathematics in the year 1999. She is fighting with F.A. since last 25 years and now she is on a wheelchair. She has some research publications on Magnetic Fluid. Recently, her paper on Mathematical Modeling of F.A. is accepted for publication. Since last 10 years, she is organizing camps for ataxia awareness and for the welfare of ataxia patients. She gave a presentation at SNCI conference held at AIIMS, Delhi in Feb 2013 and a presentation in DSHD congress on FA held at AIIMS, Delhi in April 2015.

Email: swastiwagh@gmail.com

Track Your Manuscript

Associations